Corebridge Financial Inc. Sells 861 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Corebridge Financial Inc. lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 21,784 shares of the medical research company’s stock after selling 861 shares during the period. Corebridge Financial Inc. owned 0.08% of Bio-Rad Laboratories worth $7,156,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Venturi Wealth Management LLC grew its position in shares of Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after purchasing an additional 87 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock worth $32,000 after purchasing an additional 35 shares during the period. Asset Planning Inc purchased a new stake in Bio-Rad Laboratories during the 4th quarter valued at approximately $33,000. UMB Bank n.a. raised its position in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after buying an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $38,000. 65.24% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on BIO shares. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Price Performance

BIO stock opened at $243.33 on Friday. Bio-Rad Laboratories, Inc. has a 52 week low of $241.87 and a 52 week high of $387.99. The firm has a market capitalization of $6.82 billion, a P/E ratio of -3.74 and a beta of 0.98. The company has a fifty day simple moving average of $293.54 and a two-hundred day simple moving average of $322.49. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.